Letter to the EditorThe effects of curcumin on brain-derived neurotrophic factor and cognition in schizophrenia: A randomized controlled study☆
Section snippets
Conflict of interest
In the past 3 years, MFG has received research support from Forum, has been a consultant for AbbVie, ACADIA, DSP, and Takeda; and is on the scientific board of Luc. SRM has received research support from Neurocrine and Forum and has been a consultant for Allergan, Teva, Takeda, Roche, Lundbeck, Jazz, and Forum. The remaining authors report no conflict of interest.
Contributors
Drs. Wynn, Davis, and Marder designed the study. Drs. Wynn and Hellemann conducted the data analyses. Miss Karunaratne collected blood samples and assisted with BDNF and other statistical analyses. Dr. Wynn wrote the first draft of the manuscript. Drs. Wynn, Davis, Green, and Marder edited the manuscript and helped with the interpretation of the findings. All authors contributed to and have approved the final manuscript.
Funding and disclosures
This work was supported by grant 13T-003 from the Stanley Medical Research Institute (JKW and SRM, co-PIs), NIMH Grant R01 MH095878 (MFG, PI), and by a Department of Veterans Affairs Research Enhancement Program (MFG, PI). Theravalues Corporation (Tokyo, Japan) generously donated drug and matched placebo capsules. The funding agencies and Theravalues Corporation had no further role in the design, analysis, interpretation, or decision in publication of this study. For Michael C. Davis,
Acknowledgements
The authors would like to thank Theravalues Corporation (Tokyo, Japan) for their generous donation of drug and matched placebo pills. The authors would also like to thank Aaron McNair and Gabrielle Pascual for assistance with data collection and entry.
References (10)
- et al.
Effect of curcumin on serum brain-derived neurotrophic factor levels in women with premenstrual syndrome: a randomized, double-blind, placebo-controlled trial
Neuropeptides
(2016) - et al.
Curcumin confers neuroprotection against alcohol-induced hippocampal neurodegeneration via CREB-BDNF pathway in rats
Biomed Pharmacother
(2017) - et al.
Alteration of cyclic-AMP response element binding protein in the postmortem brain of subjects with bipolar disorder and schizophrenia
J. Affect. Disord.
(2014) - et al.
Curcumin reverses the effects of chornic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB
Brain Res.
(2006) - et al.
Neuroinflammation and oxidative stress in psychosis and psychosis risk
Int. J. Mol. Sci.
(2017)
Cited by (0)
- ☆
Clinical trial registration: Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia, http://clinicaltrials.gov/, ClinicalTrials.gov identifier: NCT02104752.